LifeMD Stock Forecast for 2023 - 2025 - 2030

Updated on 04/28/2024

Stock Rating
0
Price Target
$12.00
Consensus
Outperform
Upside
0.42%
Analysts
1
Stock Rating
0
Upside
0.42%
Analysts
1
Price Target
$12.00

LifeMD Stock Forecast and Price Target

Given the average yearlong price target of $12.00 provided by prominent analysts over the past few months, there is a potential upside of approximately 0.42% from the last closing price in April, 2024 for LifeMD's stock if it is reached. This estimation is based on a high estimate of $15.00 and a low estimate of $11.00.

$12.00

0.42% Upside

Outperform
Outperform

LifeMD Fair Value Forecast for 2023 - 2025 - 2030

LifeMD's Price has seen impressive growth In the last two years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $12.85 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.

2024 Fair Value Forecast
$12.85
2025 Fair Value Forecast
$14.29
2026 Fair Value Forecast
$15.89
2027 Fair Value Forecast
$17.67
2028 Fair Value Forecast
$19.65
2029 Fair Value Forecast
$21.84
2030 Fair Value Forecast
$24.29

LifeMD Revenue Forecast for 2023 - 2025 - 2030

LifeMD's Revenue has seen impressive growth In the last three years, rising from $37.29M to $152.55M – a growth of 309.09%. In the next year, analysts believe that Revenue will reach $181.17M – an increase of 18.76%. For the next seven years, the forecast is for Revenue to grow by 23.11%.

2024 Rev Forecast
$0.18B
2025 Rev Forecast
$0.22B
2026 Rev Forecast
$0.18B
2027 Rev Forecast
$0.17B
2028 Rev Forecast
$0.18B
2029 Rev Forecast
$0.19B
2030 Rev Forecast
$0.19B

LifeMD Dividend per Share Forecast for 2023 - 2025 - 2030

LifeMD Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$0.01B
2025 FCF Forecast
$0.01B
2026 FCF Forecast
$0.01B
2027 FCF Forecast
$0.01B
2028 FCF Forecast
$0.01B
2029 FCF Forecast
$0.01B
2030 FCF Forecast
$0.01B

LifeMD EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, LifeMD's EBITDA has fallen from $-57.48M to $-7.89M – a 86.27% decrease. According to 4 prominent analysts, LifeMD's EBITDA will fall by 328.90% in the next year, reaching $18.06M. By 2030, professionals believe that LifeMD's EBITDA will decrease by 686.62%, reaching $46.28M – a concerning trend for the company.

2024 EBITDA Forecast
$0.02B
2025 EBITDA Forecast
$0.02B
2026 EBITDA Forecast
$0.04B
2027 EBITDA Forecast
$0.01B
2028 EBITDA Forecast
$0.02B
2029 EBITDA Forecast
$0.03B
2030 EBITDA Forecast
$0.05B

LifeMD EBIT Forecast for 2023 - 2025 - 2030

LifeMD's EBIT has decreased In the last three years, from $-57.82M to $-14.49M – a 74.94% drop. In the following year, 5 experts forecast LifeMD's EBIT will decrease by 56.25%, to $-6.34M. In 2030, professionals predict that LifeMD's EBIT will decrease by 42.07%, to $-8.39M.

2024 EBIT Forecast
$-6340000.00
2025 EBIT Forecast
$-1610000.00
2026 EBIT Forecast
$-4809875.00
2027 EBIT Forecast
$-10514547.08
2028 EBIT Forecast
$-16577935.89
2029 EBIT Forecast
$-7881703.32
2030 EBIT Forecast
$-8393751.31

LifeMD EPS Price Prediction Forecast for 2023 - 2025 - 2030

LifeMD's EPS has seen impressive growth In the last two years, rising from $-1.48 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $-0.42 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.

2024 EPS Forecast
$-0.42
2025 EPS Forecast
$-0.28
2026 EPS Forecast
$-0.33
2027 EPS Forecast
$-0.26
2028 EPS Forecast
$-0.31
2029 EPS Forecast
$-0.31
2030 EPS Forecast
$-0.32